---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-022298"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:06:53.290600+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma: FDA accepts NDA for ET-600 desmopressin oral solution; PDUFA Feb 25, 2026

## Summary
- FDA accepted NDA for ET-600 (desmopressin oral solution) with PDUFA target action date of February 25, 2026.
- Product has patent protection through 2044; expected to be first oral liquid option for pediatric desmopressin dosing.
- CEO states commercial preparation activities already underway for potential launch in Q1 2026.
- Caregivers currently must cut tablets or use unapproved compounding pharmacy liquids for pediatric dosing.

## SEC filing metadata
- accession: 0001437749-25-022298
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/0001437749-25-022298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-022298
- JSON: https://secwatch.observer/filing/0001437749-25-022298.json
- Plain text: https://secwatch.observer/filing/0001437749-25-022298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.